BioWorld

March 19, 2009

Medivation Cleared to Begin Pivotal Prostate Cancer Trial

Well under way with pivotal trials of Alzheimer's disease drug Dimebon, Medivation Inc. is moving into late-stage development with another product, MDV3100, an androgen receptor antagonist, in prostate cancer. (BioWorld Today) Read More

Battling FOB Bills Start March Through the House

Cost Cutting Continues: Cerus Latest Biotech to Slash Jobs

NewCo News: Auspex Focuses on Metabolism to Get More Bang from Drugs

Other News To Note

Clinic Roundup

Financings Roundup

Today's news in brief

BioWorld

BioWorld briefs for Dec. 17, 2025.

Today's news in brief

BioWorld MedTech

BioWorld MedTech briefs for Dec. 17, 2025.

Medline raises $6.3B in fourth med-tech IPO of December

BioWorld MedTech

Medline Inc. returned to the public markets with a blockbuster IPO of $6.26 billion, reportedly this year’s largest IPO globally. The upsized offering of more...

Vitesse finesse pays off: DBV wins in peanut allergy phase III

BioWorld

DBV Technologies SA’s pivotal phase III trial with the Viaskin Peanut allergy patch came through for the company, and officials plan a BLA filing with the U.S....

Acryl raises $28M IPO, aiming to bridge medical divide with AI

BioWorld MedTech

Acryl Inc. debuted on South Korea’s Kosdaq Dec. 16, raising ₩42.12 billion ($28.5 million) in an IPO. Shares (KOSDAQ:0007C0) closed at ₩67,000 on the first day,...